CRL

Charles River Laboratories International, Inc.

Industrials
174.79 -7.28 -4.00% Market Closed
2026-06-02 • USD

Key Metrics

Market Cap 8.42B
EV —
Shares Out 48.17M
Revenue (ttm) 4.03B
Net Income -184.65M
Beta —
P/E -46.34
Forward P/E —
EPS (ttm) $-3.71
P/S 2.12
P/B 2.91
P/FCF —
P/C —
EV/Sales —
EV/EBITDA —
ROA -2.39%
ROE -5.86%
ROIC —
Gross Margin —
Oper. Margin 1.75%
Profit Margin -4.59%
Debt/Eq 1.04
LT Debt/Eq 47.52%
Quick Ratio —
Current Ratio 1.36
Book/sh 60.07
Cash/sh 3.92
Div Yield —
Div TTM —
Payout Ratio —
SMA20 4.23%
SMA50 2.78%
SMA200 -0.98%
Volume 752,223
Avg Volume 974.50K
Rel Volume —
Perf Week -3.61%
Perf Month 1.43%
Perf Quarter -2.67%
Perf Half Y -5.03%
Perf YTD -12.38%
Perf Year 22.04%
Perf 3Y -12.90%
Perf 5Y -48.11%

Factor Lens

Seasonal Performance

Financial Trends

Revenue & Net Income

Earnings Per Share

Margins

Cash Flow

Company Overview

Charles River Laboratories International, Inc. is a leading, full-service, non-clinical global drug development partner with a mission to create healthier lives. The company operates through three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment provides foundational research models and services, including purpose-bred rodents and large research models, plus research model services and cell solutions. The DSA segment provides outsourced drug discovery research, non-clinical and clinical bioanalytical activities, and regulatory-required safety testing of drugs, vaccines, chemicals, and medical devices. The Manufacturing segment comprises Microbial Solutions, which provides in vitro testing methods for pharmaceuticals and consumer products, and Biologics Solutions, which provides specialized testing and contract development and manufacturing (CDMO) services for cell and gene therapies. The company serves major pharmaceutical companies, biotechnology companies, contract research organizations, hospitals, academic institutions, and government agencies globally, with operations in over 120 sites across more than 20 countries. In fiscal year 2025, total revenue was $4.0 billion.

Name
Charles River Laboratories International, Inc.
Industry
Industrials
CEO
James C. Foster · Chair, President and Chief Executive Officer
Employees
18,500 as of 2025-12-27
IPO Date
2015-11-04
Phone
(781) 222-6000
Address
251 Ballardvale Street, Wilmington, MA 01887
Website
www.criver.com

Key Executives

Name Title FY Pay
Virginia M. Wilson Retired Senior Executive Vice President and Chief Financial Officer, TIAA —
George Llado, Sr. Former Senior Vice President and Chief Information Officer, Alexion Pharmaceuticals —
Nancy C. Andrews Executive Vice President and Chief Scientific Officer, Boston Children's Hospital —
Birgit Girshick Corporate Executive Vice President & Chief Operating Officer —
James C. Foster Chair, President and Chief Executive Officer —

Latest News